Assessing Biogen’s ALS miss, plus Califf on deck

Can Biogen push another neurodegeneration therapy across the goal line at FDA?

On the latest BioCentury This Week podcast, BioCentury’s editors discuss whether Biogen Inc. (NASDAQ:BIIB) can resuscitate amyotrophic lateral sclerosis therapy tofersen after a Phase III setback as well as what other therapies ALS patients can look forward to in the clinic. The editors also check in on the state of play for the open permanent FDA commissioner post, where former Commissioner Robert Califf appears to be the front-runner, and a quartet of recent Emerging Company Profiles: China-based renal company Alebund Pharmaceuticals, newly launched cancer company Tentarix Biotherapeutics L.P., and neuroscience companies Alto Neuroscience Inc. and Origami Therapeutics Inc. Alto is a Stanford psychiatric spinout, while Origami is developing next-generation disease-modifying protein degraders and correctors.